- CEO
- Juniwati Gunawan
- Full Time Employees
- 751
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Address
- Jalan Panjang Arteri No.26 Jakarta Barat Indonesia 11520
- IPO Date
- Sep 8, 2021
- Business
- PT Kedoya Adyaraya Tbk owns and operates private hospitals in Indonesia, providing comprehensive healthcare services through its facilities including EMC Grha Kedoya Hospital in West Jakarta and EMC Cibitung Hospital (formerly Grha MM2100 Hospital) in Bekasi, West Java; core offerings encompass inpatient and outpatient rooms, operating rooms, delivery rooms, HCU, ICU, ICCU, PICU, NICU, emergency rooms, endoscopy, CT-scan, mammography, mobile X-ray, general X-ray, 4D ultrasound, fluoroscopy, catheterization laboratory, spirometry, hemodialysis, laser treatments, medical rehabilitation, pharmacy, radiology, laboratories for chemistry, hematology, microbiology, and immunology, as well as specialized centers for trauma, stroke care, cardiology, bariatric surgery, oncology, hyperbaric oxygen therapy, and robotic-assisted rehabilitation using tools such as LEXO and DIEGO; additional specialties include general surgery, orthopedics, urology, cardiothoracic surgery, neurosurgery, internal medicine, nephrology, obstetrics, gynecology, neurology, pulmonology, pediatrics, acupuncture, and occupational medicine. The company, founded in 1990 and headquartered at Jl. Panjang Arteri No. 26, Kedoya Utara, Kebon Jeruk, West Jakarta, serves patients across Indonesia with a focus on modern private hospitals featuring international-standard accreditations such as Joint Commission International (JCI) Gold Seal for EMC Grha Kedoya and Paripurna level national accreditation for both facilities; EMC Cibitung Hospital operates via subsidiary PT Sinar Medika Sejahtera. PT Kedoya Adyaraya Tbk, a subsidiary of PT Sarana Meditama Metropolitan Tbk, underwent significant ownership changes including PT Sarana Meditama Metropolitan Tbk's acquisition of a controlling 66% stake in November 2021 and an additional 13.84% stake in January 2022; it listed on the Indonesia Stock Exchange in September 2021 with 185,940,000 shares offered at IDR 200 each following OJK approval in August 2021 and executed a capital increase via public offering; recent operational investments include substantial fixed asset acquisitions and advances exceeding IDR 6 billion in the first quarter of 2025 alongside a revolving loan facility with PT Bank CIMB Niaga Tbk involving related parties PT Pratama Medika and PT Sinar Medika Sejahtera, supporting revenue growth to IDR 441.07 billion in 2024, up 18.12% from the prior year.